Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO: Deals, Investment At Risk If IPR Course Unchanged

This article was originally published in Scrip

Executive Summary

If the US Supreme Court permits the process for so-called inter partes reviews (IPRs) to remain on its current course, not only will patent claims held by innovator drug makers likely continue to be invalidated at unprecedented levels, but investment in the biopharmaceutical sector and partnering and acquisition deals among drug companies are at greater risk of falling apart, said Tom DiLenge, general counsel and head of public policy at the Biotechnology Innovation Organization (BIO).

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts